Business
Clearmind Medicine Announces Notice of Patent Publication for Depression Treatment
The notice was received by the China National Intellectual Property Administration Vancouver, Canada, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced notice of publication by the China National Intellectual Property Administration, referring to the Comp
About this update from Clearmind Medicine Inc.
[{"type":"image","alt":"Clearmind Medicine Inc.","displaySize":"","headline":null,"caption":"Clearmind Medicine Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":46,"url":"https://media.zenfs.com/en/globenewswire.com/e18eb6f6a6c8d81f644b0fcdb3ee6405"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LYbHRS3_v8ob5T6A1Lc.4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY0O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/e18eb6f6a6c8d81f644b0fcdb3ee6405","width":300,"height":46}},"lazy":false},{"type":"text","content":"The notice was received by the China National Intellectual Property Administration","length":82,"tagName":"p"},{"type":"text","content":"Vancouver, Canada, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced notice of publication by the China National Intellectual Property Administration, referring to the Company’s proprietary non hallucinogenic compound, 5-methoxy-2-aminoindane (MEAI), for the treatment of depression.","length":528,"tagName":"p"},{"type":"text","content":"According to the World Health Organization, major depressive disorder affects more than 280 million people worldwide and remains one of the leading causes of disability, with limited innovative treatment options available.","length":222,"tagName":"p"},{"type":"text","content":"Preclinical studies have demonstrated MEAI’s potential to enhance mood regulation and reduce anhedonia, offering a differentiated therapeutic approach for patients who do not respond to conventional antidepressants. This patent application further reinforces Clearmind’s robust IP portfolio, which now includes protections across multiple jurisdictions for MEAI’s applications in various mental health and addiction disorders.","length":426,"tagName":"p"},{"type":"text","content":"About Clearmind Medicine Inc.","length":39,"tagName":"p"},{"type":"text","content":"Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary object...